SALT LAKE CITY, Dec. 10, 2014 /PRNewswire/ — Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today announced it has initiated a clinical trial for its sample-to-result Staph ID/R (identification/resistance) diagnostic test. This is the second clinical trial the Company has initiated since July 2014 and, upon submission and if granted 510(k) clearance by the U.S. Food and Drug Administration (FDA), Staph ID/R will be Great Basin’s third molecular diagnostic assay. In November of this year, the Company submitted its Group B Strep assay to FDA for 510(k) clearance. In 2012 the Company launched its FDA-cleared ToxigenicC. diff assay.